Changes in Hong Kong stocks | Nuochengjianhua (09969) rose more than 5%. Recently, PSMA/STEAP1 dual-antibody ADC ICP-B381 was clinically approved

The Zhitong Finance App learned that Nuocheng Jianhua (09969) rose by more than 5%. As of press release, it had risen 5.32% to HK$14.26, with a turnover of HK$22.5916 million.

According to news, according to Nuochengjian's official WeChat account, recently, ICP-B381, a new dual-antibody ADC drug targeting PSMA and STEAP1 developed independently by the company, was approved by the National Drug Administration (NMPA) Drug Evaluation Center (CDE) to conduct clinical trials to treat solid tumors such as prostate cancer. This is the company's first dual-antibody ADC approved clinically, and the company's third innovative ADC drug to enter clinical trials. PSMA and STEAP1 are significantly highly expressed in prostate cancer cells and are highly potential treatment targets for prostate cancer, especially metastatic castration-resistant prostate cancer (mCRPC). Currently, no dual-antibody ADC targeting PSMA and STEAP1 has been approved for marketing in the world.

ICP-B381 is the first dual-antibody ADC developed by Nuochengjianhua based on a self-developed ADC platform. It combines a humanized anti-PSMA/STEAP1 antibody, a next-generation irreversible connector independently developed by the company, and a powerful payload. Preclinical studies have shown that ICP-B381 showed potent, dose-dependent anti-tumor activity in a 22Rv1 prostate cancer xenograft model. At the same dosage, the efficacy is superior to the corresponding single-target PSMA‑ADC and STEAP1‑ADC, and the tolerability is good.